Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register DEA schedulingSchedule I controlled substancessynthetic…
DEA Places Four Synthetic Cannabinoids in Schedule I
The Drug Enforcement Administration has placed four synthetic cannabinoids into Schedule I due to their high abuse potential and lack of accepted medical use. These DEA Schedule I synthetic cannabinoids include 4F-MDMB-BUTICA, ADB-4en-PINACA,…
DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I
The U.S. Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid analog, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This CUMYL-PEGACLONE Schedule I…
Cannabis News Mix: June 2026 Law Enforcement and Industry Updates
This cannabis news mix reviews six articles from June 2026 covering law enforcement encounters, synthetic cannabinoid toxicity, and cannabis industry developments. Dr. Caplan provides clinical commentary on regulatory fragmentation and public safety…
In the Mix: Synthetic Cannabinoid Arrests and Clinical Insights
Synthetic cannabinoid arrests highlight ongoing public health challenges in 2026. These arrests often involve heroin, complicating substance use disorder treatment. Understanding synthetic cannabinoid arrests is crucial for clinicians and law enforcement.
In the Mix: Synthetic Cannabinoid Trafficking Update — May 21, 2026
This article reviews synthetic cannabinoid trafficking and its clinical impact in 2026. Synthetic cannabinoid trafficking poses unique risks compared to regulated cannabis. Clinicians should be aware of these developments for informed patient care.
Mouse Study on Prenatal Cannabinoid Effects on Fetal Brain Vasculature
This mouse study investigates prenatal cannabinoid fetal brain effects, showing reduced blood flow in fetal brain vasculature. The research used a synthetic cannabinoid with dose-related vessel diameter reductions. However, human relevance remains…
Analytical Challenges and Emerging Detection Strategies of Synthetic Cannabinoids in Horse Doping Control.
Synthetic cannabinoids (SCs) were originally synthesized to advance the understanding of the endocannabinoid system, facilitate disease research, and support...
Synthetic cannabinoids in Mayotte over a year in time and space: an example of high-frequency evolution of market.
Researchers used synthetic cannabinoid wastewater monitoring surveillance to track market evolution in Mayotte over one year. The environmental monitoring approach revealed rapid changes in synthetic cannabinoid composition and geographic distribution,…
Acute toxicity of ADB-CHMINACA – a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome.
A new case series reveals that synthetic cannabinoid toxicity emergency treatment protocols are urgently needed as ADB-CHMINACA causes rapid-onset seizures and encephalopathy. Emergency physicians document severe neurologic complications occurring within…